口苦怎么回事Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
期刊名称： American Journal of Transplantation
流行词作者： M. D. Pescovitz
清炖鳗鱼
伤心的往事年份： 2010年
期号： 第5p1期
一件难忘的事500字关键词： Chemistry, Organic
摘要：Rituximab, chimeric anti-human CD20, is approved for treatment of B-cell lymphoma in adults. It is being ud experimentally in other various immune-related dias such as immune thrombocytopenic purpura, systemic lupus erythematosus, myasthenia gravis and rheumatoid arthritis. In transplant recipients, it is ud for treatment of post-transplant lymphoproliferative dia, to anecdotally reduce pre-formed anti-HLA and anti-ABO antibodies and for the prevention and treatment of acute rejection. This article primarily reviews the science behind rituximab: its history, pharmacokinet
道德缺失
ics and potential mechanism of action. A need for controlled clinical trials is clearly indicated before the widespread u of this drug in transplant.
杂粮煎饼学习内容由中国教育图书进出口有限公司引进
营养顾问
